CTOs on the Move

STERIS IMS

www.imsteris.com

 
STERIS Instrument Management Services is a surgical device and instrument management and consulting company.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.imsteris.com
  • 3316, 2nd Avenue North
    Birmingham, AL USA 35222
  • Phone: 800.783.9251

Executives

Name Title Contact Details

Similar Companies

Professional Gem Sciences Inc

Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Communications Group

MD Communications Group is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shire plc

Shire plc is a Radford, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)